Year: 2006
Type: article
Abstract: Comment on Milligan et al, page [4614][1]
In this issue of Blood , Milligan and colleagues report that survival was shorter ( P = .05) in high-risk patients randomized to receive, generally as salvage therapy, the widely used combination of fludarabine and cytarabine (FLA) rather than standard
Source: Blood
Author: Elihu Estey
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2048410913